Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 12

Tailoring Immunotherapy Strategies for the Advanced NSCLC

March 28, 2025

Benjamin P. Levy, MD, Misty D. Shields, MD, PhD

Panelists discuss how treatment decisions for advanced non–small cell lung cancer (NSCLC) without actionable mutations depend on factors like PD-L1 status, histology (eg, squamous [SQ]), and biomarkers like STK11/KEAP1. Chemotherapy may be added based on individual patient factors, with promising advancements expected in 2025.

EP. 1: An Expert Insights on Recent Advancements in LS-SCLC

EP. 2: The Key Updates in the Treatment of ES-SCLC

EP. 3: An Expert Perspectives on Tarlatamab in ES-SCLC

EP. 4: Looking Ahead With SCLC: ADCs and Other Novel Agents

EP. 5: The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP. 6: Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP. 7: The New Targeted Approaches in Unresectable Early-Stage NSCL

EP. 8: Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP. 9: Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP. 10: Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations

EP. 11: The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

Now Viewing

EP. 12: Tailoring Immunotherapy Strategies for the Advanced NSCLC

Video content above is prompted by the following:

How do you select between mono immunotherapy (IO) and dual IO therapy in patients with advanced NSCLC and no actionable mutations?
In which patients do you consider the addition of chemotherapy?
How does PD-L1 status influence your decision?
What is your preferred management strategy for patients with SQ histology? STK11 or KEAP1? What data influence your treatment approach?
What advancements in lung cancer from 2024 will have the most significant impact on your clinical practice in 2025?
What do you see as the greatest treatment gaps and unmet needs in the management of advanced NSCLC, and what are the most promising opportunities for future advancements?